IA
ANIK icon

Icon Advisers’s Anika Therapeutics ANIK Stock Holding History

Icon Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-19,000
Closed -$782K – 334
2015
Q1 		$782K Buy
+19,000
New +$768K 0.05% 258

Other funds holding ANIK

TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Icon Advisers's ANIK Position: Q2 2015 in Review

Icon Advisers sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 19,000 shares — an estimated $782K sold.

Icon Advisers first reported a position in ANIK in Q1 2015 and held it in 1 quarter. The position peaked at $782K in Q1 2015. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

  • Icon Advisers reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Icon Advisers sold 19,000 Anika Therapeutics shares in Q2 2015, an estimated $782K.
  • Icon Advisers first reported a position in Anika Therapeutics in Q1 2015 and held it in 1 quarter.
  • Icon Advisers's Anika Therapeutics position peaked at $782K in Q1 2015.
  • 136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on Icon Advisers's 13F filing for Q2 2015, filed 5 Aug 2015.